Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arcus Biosciences
Biotech
Gilead loses interest in Arcus' rival to Merck's Welireg
Gilead has defied analysts’ expectations by passing on its chance to license Arcus’ potential rival to Merck & Co.’s kidney cancer drug Welireg.
James Waldron
Feb 18, 2025 8:19am
Flagship vet plants CEO roots at Pharming—Chutes & Ladders
Jan 24, 2025 8:30am
Arcus drops promising data on HIF-2a candidate in kidney cancer
Oct 24, 2024 2:48pm
Gilead backs out of option to buy immunotherapy-focused Tizona
Feb 6, 2024 7:15pm
Gilead stops phase 3 TIGIT trial, doubles down on other studies
Jan 30, 2024 8:09am
Arcus, Gilead drop A2R inhibitor in prostate cancer
Aug 7, 2023 11:00am
